Zevra Therapeutics (ZVRA) Capital Expenditures (2014 - 2026)
Zevra Therapeutics (ZVRA) reported Capital Expenditures of $35000.0 for Q1 2026, down 64.65% on a YoY basis from $99000.0 in Q1 2025, and up 212.9% quarter-over-quarter from -$31000.0 in Q4 2025.
Zevra Therapeutics (ZVRA) Capital Expenditures (2014 - 2026) Analysis & Trends
Zevra Therapeutics has reported Capital Expenditures for 12 years, with the latest figure at $35000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 64.65% year-over-year to $35000.0; the trailing twelve-month figure through Mar 2026 stood at $771000.0 (up 678.79% YoY), and the FY2025 full-year result was $835000.0, changed N/A from the prior year.
- Capital Expenditures for Q1 2026 stood at $35000.0, up from -$31000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $554000.0 in Q3 2025, with the low at -$31000.0 in Q4 2025.
- Historically, Capital Expenditures has averaged $96846.2 across 4 years, with a median of $34000.0 in 2022.
- Annual changes were most pronounced in 2023 — Capital Expenditures jumped 514.29% — and 2026, when it tumbled 64.65%.
- Zevra Therapeutics' Capital Expenditures stood at $34000.0 in 2022, then soared by 111.76% to $72000.0 in 2023, then tumbled by 143.06% to -$31000.0 in 2025, then jumped by 212.9% to $35000.0 in 2026.
- The last three Capital Expenditures figures came in at $35000.0 (Q1 2026), -$31000.0 (Q4 2025), and $554000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -63,220.27 |
| 10 | Zevra Therapeutics | 796.95 Mn | 596.33 Mn | 34.30 Mn | 35,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35,000.00 |
| Mar 31, 2026 | 35,000.00 |
| Dec 31, 2025 | -31,000.00 |
| Dec 31, 2025 | -31,000.00 |
| Sep 30, 2025 | 554,000.00 |
| Sep 30, 2025 | 554,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Mar 31, 2025 | 99,000.00 |
| Mar 31, 2025 | 99,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Sep 30, 2023 | 172,000.00 |
| Sep 30, 2023 | 172,000.00 |
| Jun 30, 2023 | 23,000.00 |
| Jun 30, 2023 | 23,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Dec 31, 2022 | 34,000.00 |
| Dec 31, 2022 | 34,000.00 |